Literature DB >> 6602550

Brief report: linkage between G6PD and fragile-X syndrome.

G Filippi, A Rinaldi, N Archidiacono, M Rocchi, I Balazs, M Siniscalco.   

Abstract

Eighteen Sardinian pedigrees segregating for the X-fragile site syndrome were studied with respect to the segregation of the fragile site (FS) at Xq28, mental retardation, and macro-orchidism. No exception was found in the association of this symptomatic triad (MOM-X) in 41 out of 42 patients examined. The exceptional individual had micro- rather than macro-orchidism and was found to have a 47, XXY sex chromosome complement. In six informative sibships, the MOM-X syndrome was found to segregate in close linkage association with G6PD-deficiency or protan colorblindness. The maximum likelihood estimate of recombination if 6% with 90% fiducial limits between 2.5 and 19.5% and an odds ratio in favor of measurable linkage of 428:1. However, no hint of measurable linkage was found in six pedigrees segregating for G6PD and the Renpenning syndrome or other unspecified types of X-linked mental retardation. These data give strong support to the generally held hypothesis that the FS at Zq28, characteristic of the MOM-X syndrome, is a direct expression of a genetic change in the same chromosomal region. They also clearly suggest that X-linked MR without FS may be the result of different allelic mutations at the same locus.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6602550     DOI: 10.1002/ajmg.1320150115

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  9 in total

Review 1.  Comparative map for mice and humans.

Authors:  J H Nadeau; M T Davisson; D P Doolittle; P Grant; A L Hillyard; M R Kosowsky; T H Roderick
Journal:  Mamm Genome       Date:  1992       Impact factor: 2.957

Review 2.  Comparative map for mice and humans.

Authors:  J H Nadeau; M T Davisson; D P Doolittle; P Grant; A L Hillyard; M Kosowsky; T H Roderick
Journal:  Mamm Genome       Date:  1991       Impact factor: 2.957

3.  The telomeric region of the human X chromosome long arm: presence of a highly polymorphic DNA marker and analysis of recombination frequency.

Authors:  I Oberlé; D Drayna; G Camerino; R White; J L Mandel
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

4.  Mental retardation in heterozygotes for the fragile-X mutation: evidence in favor of an X inactivation-dependent effect.

Authors:  M Rocchi; N Archidiacono; A Rinaldi; G Filippi; G Bartolucci; G S Fancello; M Siniscalco
Journal:  Am J Hum Genet       Date:  1990-04       Impact factor: 11.025

5.  Manifestation of the fragile site Xq27 in fibroblasts. IV. Clones from a heterozygous female do not manifest this site homogeneously on either the early or late replicating X chromosome.

Authors:  G Barbi; P Steinbach; S Baur; W Vogel
Journal:  Hum Genet       Date:  1985       Impact factor: 4.132

6.  Linkage analysis using multiple Xq DNA polymorphisms in normal families, families with the fragile X syndrome, and other families with X linked conditions.

Authors:  J M Connor; L A Pirrit; J R Yates; J A Crossley; S J Imrie; J M Colgan
Journal:  J Med Genet       Date:  1987-01       Impact factor: 6.318

7.  Genetic mapping of DNA segments relative to the locus for the fragile-X syndrome at Xq27.3.

Authors:  L M Mulligan; M A Phillips; C J Forster-Gibson; J Beckett; M W Partington; N E Simpson; J J Holden; B N White
Journal:  Am J Hum Genet       Date:  1985-05       Impact factor: 11.025

8.  Cytological mapping of the human glucose-6-phosphate dehydrogenase gene distal to the fragile-X site suggests a high rate of meiotic recombination across this site.

Authors:  P Szabo; M Purrello; M Rocchi; N Archidiacono; B Alhadeff; G Filippi; D Toniolo; G Martini; L Luzzatto; M Siniscalco
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

9.  The human genes for hemophilia A and hemophilia B flank the X chromosome fragile site at Xq27.3.

Authors:  M Purrello; B Alhadeff; D Esposito; P Szabo; M Rocchi; M Truett; F Masiarz; M Siniscalco
Journal:  EMBO J       Date:  1985-03       Impact factor: 11.598

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.